Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CR845 in hemodialysis patients with moderate-to-severe pruritus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Related Pruritus
• Uremic Pruritus

Drugs mentioned

• CR845 (difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Uremic Pruritus | Phase 3 | Status: COMPLETED | Results posted: 2022-04-26